The UK DRI is breaking new ground by drawing world-leaders in dementia research into a single national institute, led by Professor Bart De Strooper.
The UK DRI will bring together world-leaders in dementia research into a single national institute that will be defined by close collaboration and access to exceptional research resources. Collectively they will bring a range of technological and intellectual approaches to the problem.
And by studying all of the dementias, UK DRI researchers will both identify commonalities across different neurodegenerative disorders, and distinguish unique features of specific forms of dementia.
This early-stage investigation of how dementias develop and progress combined with our firm commitment to translation, will bring therapies to patients faster. It will be catalytic for discovering new ways to diagnose, treat and prevent dementias, and to find better ways to care for patients.
The UK DRI will connect, amplify and revolutionise dementia research.
The UK DRI is a joint £290 million investment from the Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK.
The UK DRI wants to make a big impact, but we know the institute cannot transform the outlook for people with dementia on its own. The UK DRI will build on and connect to the strong dementia research landscape that exists across the UK. In particular, the institute will connect to the strengths of the MRC Dementias Platform UK (DPUK), the NIHR Translational Collaboration in Dementia Research and the recent Momentum research awards for dementia. The UK DRI will also align with charity-led initiatives such as the Alzheimer’s Research UK’s Drug Discovery Alliance, and Brains for Dementia Research which is funded by Alzheimer’s Society, Alzheimer’s Research UK and the MRC.
The UK DRI will not work alone; it will proactively seek additional charity, industry, national and international partners in delivering its mission.